SCHEMBL29526353

SCHEMBL29526353

COc1cc2c(cc1Nc1ncc(C(N)=O)c(Nc3ccccc3F)n1)CN(C)CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29525877 0.93 MAP4K1 (1.00) MAP4K1
SCHEMBL29526134 0.92 MAP4K1 (1.00) MAP4K1
SCHEMBL26970262 0.92 MAP4K1 (1.00) MAP4K1
SCHEMBL29525933 0.91 MAP4K1 (0.84) MAP4K1
SCHEMBL29526482 0.91 MAP4K1 (0.84) MAP4K1
SCHEMBL29526423 0.91 MAP4K1 (1.00) MAP4K1
SCHEMBL29526009 0.90 MAP4K1 (0.86) MAP4K1
SCHEMBL29526058 0.90 MAP4K1 (0.86) MAP4K1
SCHEMBL29525808 0.90 MAP4K1 (1.00) MAP4K1
SCHEMBL29525984 0.90 MAP4K1 (1.00) MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240362-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 Merck Sharp & Dohme LLC (US) 2023-09-13 — — EP claimed
WO-2022098809-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 MERCK SHARP & DOHME CORP. (US) 2022-05-12 — — WO claimed
US-20230416225-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 MERCK SHARP & DOHME LLC (US) 2023-12-28 — — US disclosed
EP-4240362-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 Merck Sharp & Dohme LLC (US) 2023-09-13 — — EP disclosed
WO-2022098809-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 MERCK SHARP & DOHME CORP. (US) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416225-A1 DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 PDXK, PHKG1, PHKG2 MAP4K1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback